Blue Chip Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $41.6M | Buy |
191,381
+1,629
| +0.9% | +$361K | 3% | 8 |
|
|
2025
Q4 | $43.4M | Buy |
189,752
+771
| +0.4% | +$176K | 3.14% | 8 |
|
|
2025
Q3 | $43.8M | Buy |
188,981
+708
| +0.4% | +$144K | 3.27% | 7 |
|
|
2025
Q2 | $34.9M | Buy |
188,273
+2,975
| +2% | +$553K | 2.85% | 9 |
|
|
2025
Q1 | $38.8M | Buy |
185,298
+2,382
| +1% | +$463K | 3.35% | 4 |
|
|
2024
Q4 | $32.5M | Buy |
182,916
+1,578
| +0.9% | +$290K | 2.79% | 8 |
|
|
2024
Q3 | $35.8M | Sell |
181,338
-1,190
| -0.7% | -$222K | 3.11% | 7 |
|
|
2024
Q2 | $31.3M | Buy |
182,528
+5,308
| +3% | +$879K | 2.89% | 8 |
|
|
2024
Q1 | $32.3M | Sell |
177,220
-2,219
| -1% | -$382K | 3.13% | 6 |
|
|
2023
Q4 | $27.8M | Buy |
179,439
+2,374
| +1% | +$346K | 2.9% | 8 |
|
|
2023
Q3 | $26.4M | Buy |
177,065
+4,337
| +3% | +$637K | 3.15% | 7 |
|
|
2023
Q2 | $23.3M | Sell |
172,728
-987
| -0.6% | -$145K | 2.64% | 10 |
|
|
2023
Q1 | $27.7M | Sell |
173,715
-2,666
| -2% | -$408K | 3.28% | 5 |
|
|
2022
Q4 | $28.5M | Sell |
176,381
-14,667
| -8% | -$2.25M | 3.55% | 4 |
|
|
2022
Q3 | $25.6M | Buy |
191,048
+5,182
| +3% | +$744K | 3.51% | 4 |
|
|
2022
Q2 | $28.5M | Buy |
185,866
+2,470
| +1% | +$377K | 3.63% | 2 |
|
|
2022
Q1 | $29.7M | Buy |
183,396
+864
| +0.5% | +$126K | 3.7% | 4 |
|
|
2021
Q4 | $24.7M | Buy |
182,532
+5,267
| +3% | +$622K | 3.1% | 8 |
|
|
2021
Q3 | $19.1M | Buy |
177,265
+3,507
| +2% | +$401K | 2.69% | 12 |
|
|
2021
Q2 | $19.6M | Buy |
173,758
+4,231
| +2% | +$477K | 2.79% | 11 |
|
|
2021
Q1 | $18.3M | Sell |
169,527
-6,016
| -3% | -$643K | 2.82% | 10 |
|
|
2020
Q4 | $18.8M | Buy |
175,543
+7,873
| +5% | +$757K | 2.94% | 8 |
|
|
2020
Q3 | $14.7M | Buy |
167,670
+3,807
| +2% | +$358K | 2.61% | 13 |
|
|
2020
Q2 | $16.1M | Buy |
163,863
+7,497
| +5% | +$660K | 3.15% | 5 |
|
|
2020
Q1 | $11.9M | Sell |
156,366
-4,529
| -3% | -$386K | 2.96% | 8 |
|
|
2019
Q4 | $14.2M | Buy |
160,895
+13,008
| +9% | +$1.08M | 2.71% | 6 |
|
|
2019
Q3 | $11.2M | Buy |
147,887
+14,315
| +11% | +$981K | 2.37% | 15 |
|
|
2019
Q2 | $9.71M | Buy |
133,572
+10,071
| +8% | +$792K | 2.18% | 16 |
|
|
2019
Q1 | $9.95M | Buy |
123,501
+12,227
| +11% | +$1M | 2.36% | 13 |
|
|
2018
Q4 | $10.3M | Sell |
111,274
-425
| -0.4% | -$37.4K | 2.58% | 6 |
|
|
2018
Q3 | $10.6M | Buy |
111,699
+5,038
| +5% | +$478K | 2.58% | 7 |
|
|
2018
Q2 | $9.88M | Buy |
106,661
+5,396
| +5% | +$527K | 2.62% | 5 |
|
|
2018
Q1 | $9.59M | Buy |
101,265
+5,322
| +6% | +$585K | 2.65% | 4 |
|
|
2017
Q4 | $9.28M | Buy |
95,943
+1,107
| +1% | +$104K | 2.74% | 5 |
|
|
2017
Q3 | $8.43M | Buy |
94,836
+3,903
| +4% | +$297K | 2.71% | 5 |
|
|
2017
Q2 | $6.59M | Buy |
90,933
+5,124
| +6% | +$344K | 2.3% | 7 |
|
|
2017
Q1 | $5.59M | Buy |
85,809
+3,501
| +4% | +$220K | 2.12% | 11 |
|
|
2016
Q4 | $5.15M | Buy |
82,308
+11,664
| +17% | +$712K | 2.02% | 10 |
|
|
2016
Q3 | $4.46M | Buy |
70,644
+3,793
| +6% | +$246K | 1.97% | 12 |
|
|
2016
Q2 | $4.14M | Buy |
66,851
+3,831
| +6% | +$233K | 1.86% | 16 |
|
|
2016
Q1 | $3.6M | Buy |
63,020
+3,111
| +5% | +$173K | 1.75% | 21 |
|
|
2015
Q4 | $3.55M | Buy |
59,909
+7,562
| +14% | +$436K | 1.85% | 18 |
|
|
2015
Q3 | $2.85M | Buy |
52,347
+4,090
| +8% | +$266K | 1.81% | 21 |
|
|
2015
Q2 | $3.24M | Buy |
48,257
+5,600
| +13% | +$366K | 2.07% | 16 |
|
|
2015
Q1 | $2.5M | Sell |
42,657
-45
| -0.1% | -$2.72K | 1.69% | 25 |
|
|
2014
Q4 | $2.79M | Buy |
+42,702
| New | +$2.69M | 1.95% | 20 |
|
Other funds holding ABBV
VCM
VPM
Blue Chip Partners's ABBV Position: Q1 2026 in Review
Blue Chip Partners increased its AbbVie (ABBV) stake by 0.86% in Q1 2026, buying an estimated $361K and bringing the position to 191,381 shares worth $41.6M. The position accounts for 3% of the portfolio, ranked #8.
Blue Chip Partners first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. The position peaked at $43.8M in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Blue Chip Partners held 191,381 shares of AbbVie worth $41.6M as of Q1 2026.
- Blue Chip Partners bought 1,629 AbbVie shares in Q1 2026, an estimated $361K.
- AbbVie made up 3% of Blue Chip Partners's portfolio in Q1 2026, its #8 holding.
- Blue Chip Partners first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
- Blue Chip Partners's AbbVie position peaked at $43.8M in Q3 2025.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Blue Chip Partners's 13F filing for Q1 2026, filed 15 May 2026.